Stratos Investment Management LLC Purchases 32,559 Shares of Novo Nordisk A/S (NYSE:NVO)

Stratos Investment Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 63.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,046 shares of the company's stock after purchasing an additional 32,559 shares during the quarter. Stratos Investment Management LLC's holdings in Novo Nordisk A/S were worth $5,836,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. BIP Wealth LLC lifted its stake in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock valued at $313,000 after acquiring an additional 138 shares during the last quarter. Xponance Inc. lifted its stake in shares of Novo Nordisk A/S by 4.9% in the 4th quarter. Xponance Inc. now owns 3,156 shares of the company's stock valued at $271,000 after acquiring an additional 146 shares during the last quarter. Mystic Asset Management Inc. lifted its stake in shares of Novo Nordisk A/S by 1.2% in the 4th quarter. Mystic Asset Management Inc. now owns 13,185 shares of the company's stock valued at $1,134,000 after acquiring an additional 150 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 31,670 shares of the company's stock valued at $2,724,000 after acquiring an additional 151 shares during the last quarter. Finally, Diversified Enterprises LLC lifted its stake in shares of Novo Nordisk A/S by 2.8% in the 4th quarter. Diversified Enterprises LLC now owns 6,388 shares of the company's stock valued at $549,000 after acquiring an additional 172 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Down 2.9%

Shares of NVO stock traded down $2.08 during midday trading on Friday, reaching $68.93. 6,511,310 shares of the stock were exchanged, compared to its average volume of 7,316,084. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $143.49. The firm has a market cap of $307.77 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. The company's 50 day moving average is $70.35 and its two-hundred day moving average is $75.08. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion during the quarter. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.